Anderson C, et al. - Researchers focused on risk vs advantage of chemoprevention among women with a first-degree family history of breast cancer who started tamoxifen or raloxifene outside of a clinical trial setting. In The Sister Study, participants self-reported the use of raloxifene and tamoxifen for chemoprevention from 2014 to 2016. Matching of 432 current raloxifene users to 4,307 nonusers and 96 current tamoxifen users to 953 nonusers was done on age and year of cohort enrollment, following exclusions. No proof of a net benefit was obtained in 44% and 5% of tamoxifen users and raloxifene users, respectively, among current chemoprevention users. Raloxifene use, but not tamoxifen use, was significantly predicted by the presence of strong evidence of benefit. Findings revealed a more common use of raloxifene vs tamoxifen as a prophylaxis against the development of breast cancer. The benefit was likely to be seen in most of the raloxifene users but in < 60% of tamoxifen users. An informed decision regarding breast cancer chemoprevention can be made with the help of risk-benefit tables.